Possibilities of antiplatelet therapy in non-cardioembolic ischemic stroke

Most patients survive their first non-cardioembolic ischemic stroke (IS), but a significant proportion of them experience second within the year. The main directions for prevention recurrent IS are antihypertensive and lipid-lowering therapy, control glucose levels in with diabetes mellitus, smoking cessation. Clinical guidelines recommend use antiplatelet therapy noncardioembolic or transient attack (TIA). administration agents to who have had TIA reduces risk by 23% overall vascular events (myocardial infarction, stroke, death from cardiovascular disease) 17% (Antithrombotic Trialists' Collaboration, 2009). Acetylsalicylic acid (ASA), combined clopidogrel ASA, combination ASA sustained release dipyridamole been shown be effective secondary IS. Intensive increases frequency bleeding.